ABVC BioPharma (NASDAQ:ABVC) Releases Quarterly Earnings Results, Beats Expectations By $0.36 EPS

ABVC BioPharma (NASDAQ:ABVC) issued its quarterly earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.36, FiscalAI reports.

ABVC BioPharma Price Performance

Shares of ABVC BioPharma stock traded down $0.03 during trading on Tuesday, hitting $0.99. 34,952 shares of the company were exchanged, compared to its average volume of 100,511. The firm has a market capitalization of $26.42 million, a P/E ratio of -3.30 and a beta of 0.47. ABVC BioPharma has a 1-year low of $0.71 and a 1-year high of $3.06. The firm’s fifty day moving average price is $1.01 and its 200 day moving average price is $1.23.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners. ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.